English | 简体中文 | 繁體中文 | 한국어 | 日本語
 Press Releases for Monday, October 21, 2024
Acrometa Group to Divest Its Life Sciences Business, Pursue New Business Opportunities in the Region 
22:50 HKT/SGT
GMG Provides Business Update on Australian Federal Government Engagement 
20:29 HKT/SGT
FishWar Officially Powered by Sei: Elevating the GameFi Experience 
20:00 HKT/SGT
Hong Kong International Wine & Spirits Fair opens next month 
19:39 HKT/SGT
康哲藥業入選2024年度「中國醫藥上市公司ESG競爭力」系列榜單 
19:18 HKT/SGT
康哲药业入选2024年度“中国医药上市公司ESG竞争力”系列榜单 
19:15 HKT/SGT
FishWar Officially Powered by Sei: Elevating the GameFi Experience 
19:00 HKT/SGT
三菱重工、人事異動を発表 
16:00 HKT/SGT
JCBと富士通、中央銀行デジタル通貨を活用した、異なるキャッシュレスサービス間での取引実現に向け、ホワイトペーパーを発行 
16:00 HKT/SGT
Majority of Singapore Employees Comfortable Discussing Mental Health at Work, foundit Survey Reveals 
16:00 HKT/SGT
GTJAI Wins Multiple Awards at HKQAA Hong Kong Green and Sustainable Finance Awards 2024 
15:48 HKT/SGT
國泰君安國際榮獲HKQAA香港綠色和可持續金融大奬 2024多項殊榮 
15:44 HKT/SGT
国泰君安国际荣获HKQAA香港绿色和可持续金融大奬 2024多项殊荣 
15:40 HKT/SGT
Learn & Get Inspired at the Global STEM Confex 
15:00 HKT/SGT
TOYOTA GAZOO Racing closes the gap before the final round 
12:27 HKT/SGT
Everest Medicines Announces Taiwan TFDA Approval of NEFECON for the Treatment of Primary IgA Nephropathy 
12:19 HKT/SGT
云顶新耀宣布中国台湾地区药政部门批准全球首个对因治疗IgA肾病药物耐赋康®的新药上市许可申请 
12:08 HKT/SGT
雲頂新耀宣佈中國台灣地區藥政部門批准全球首個對因治療IgA腎病藥物耐賦康®的新藥上市許可申請 
11:44 HKT/SGT
Ching Lee Holdings practices CSR to promote sustainability in the construction industry 
11:12 HKT/SGT
JCB and GHL Expand Payment Options across Malaysia, Thailand and the Philippines 
11:00 HKT/SGT
正利控股推动建筑业可持续发展与企业社会责任实践 
10:56 HKT/SGT
正利控股推動建築業可持續發展與企業社會責任實踐 
10:01 HKT/SGT
China Medical System: First Ruxolitinib Cream's Prescriptions for Vitiligo Issued in the Greater Bay Area 
10:00 HKT/SGT
 ACN Search:
 
Andy Pitre, EVP of Product, HubSpot, launching Breeze at INBOUND 2024
 
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575